Helen Chew, M.D.

Helen K. Chew, M.D.

Specialties

Breast Cancer

Hematology/Oncology

Internal Medicine

Department

Internal Medicine

Title

  • Professor
  • Director, Clinical Breast Cancer Program
  • Director, Hematology and Oncology Fellowship Program

Reviews

To see if Helen K. Chew is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

UC Davis Comprehensive Cancer Center

2279 45th Street
Sacramento, CA 95817
Driving Directions

Primary Phone:
800-362-5566
916-734-5959

Additional Phone Numbers

Clinic Fax: 916-703-5265
Clinic Referral Phone: 916-703-5210
Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Clinical Interests

Helen K. Chew is the leader of the UC Davis Cancer Center clinical breast cancer program. She is responsible for coordinating surgical, medical and radiation oncology services and clinical trials for breast cancer.

Research/Academic Interests

Dr. Chew's research interests involve novel treatments for breast cancer, serum tumor markers, complications of, cancer, including thromboembolism, and treatment-related cognitive dysfunction.

Division

Hematology and Oncology

Center/Program Affiliation

UC Davis Comprehensive Cancer Center

Education

M.D., University of Texas Health Sciences Center, San Antonio TX 1991

B.S., Stanford University, Stanford CA 1986

Internship: Internal Medicine, University of Texas Health Sciences Center, San Antonio TX 1991-1994

Residency

Internal Medicine, University of Texas Health Sciences Center, San Antonio TX 1991-1994

Fellowships

Hematology/Oncology, University of Texas Health Sciences Center, San Antonio TX, 1995-1998

Molecular Medicine, University of Texas Health Sciences Center, San Antonio TX, 1996-2000

Board Certifications

American Board of Internal Medicine,

American Board of Internal Medicine, Medical Oncology,

CA Medical Board, License,

Texas Medical Board,

Professional Memberships

American Society of Clinical Oncology

Fellow, American College of Physicians

Southwest Oncology Group

Honors and Awards

UC Davis Health System Faculty Recognition Certificate of Excellence and Achievement Award, 2007, 2008

Find a Cure Award, South Placer Breast Cancer Endowment, 2007

Joyce Raley Teel Award for outstanding dedication to the cause of breast cancer, 2006

Christine & Helen Landgraf Memorial Award, 2001

VA Career Development Award, 1998

Chief Resident, Department of Internal Medicine, 1994, 1995

Select Recent Publications

For a comprehensive list of Dr. Chew's publications, please click here (opens new window).

Ho C, Davies AM, Sangha RS, Lau D, Lara P, Chew HK, Beckett L, Mack PC, Riess JW, Gandara DR. Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer. Invest New Drugs. 2013 Dec;31(6):1587-91. doi:10.1007/s10637-013-0024-y.

Schott AF, Barlow WE, Albain KS, Chew HK, Wade JL, Lanier KS, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430. Oncologist. 2012;17(2):179-87. doi:10.1634/theoncologist.2011-0235.

Barnhard S, Pai A, Chew HK, Song JY. Richter's syndrome with aberrant CD2 and CD4 expression. J Clin Oncol. 2012 Sep 10;30(26):e243-5. doi:10.1200/JCO.2011.40.2065.

Chew HK, Somlo G, Mack PC, Gitlitz B, Gandour-Edwards R, Christensen S, Linden H, Solis LJ, Yang X, Davies AM. Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. Ann Oncol. 2012 Apr;23(4):1023-9. doi:10.1093/annonc/mdr328.

Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, Chew HK, Gaynor ER, Hayes DF, Epstein A, Albain KS. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol. 2010 Apr 1;28(10):1671-6. doi:10.1200/JCO.2008.20.2119.

Sandhu R, Pan CX, Wun T, Harvey D, Zhou H, White RH, Chew HK. The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer. Cancer. 2010 Jun 1;116(11):2596-603. doi:10.1002/cncr.25004.

de Leoz ML, Young LJ, An HJ, Kronewitter SR, Kim J, Miyamoto S, Borowsky AD, Chew HK, Lebrilla CB. High-Mannose Glycans are Elevated during Breast Cancer Progression. Mol Cell Proteomics. 2010 Jan;10(1):M110.002717. doi:10.1074/mcp.M110.002717.

Ku G, Chew HK, Harvey DJ, Zhou H, White RH, Wun T. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and mortality. Blood. 2009 Apr 23;113(17):3911-3917. doi:10.1182/blood-2008-08-175745.

Barkauskas DA, An HJ, Kronewritter SR, deLeoz ML, Chew HK, de Vere-White RW, Leiserowitz GS, Miyamoto S, Lebrilla CB, Rocke DM. Detecting glycan cancer biomarkers in serum samples using MALDI FT-ICR mass spectrometry data. Bioinformatics. 2009 Jan 15;25(2):251-257. doi:10.1093/bioinformatics/btn610.

Chew HK, Doroshow J, Frankel P, Margolin K, Somlo G, Lenz HJ, Gordon M, Zhang W, Yang D, Russell C, Spicer D, Synold T, Bayer R, Hantel A, Stiff P, Gandara DR, Albain K. Phase II Studies of Gemcitabine and Cisplatin in Heavily and Minimally Pretreated Metastatic Breast Cancer. J Clin Oncol. 2009 May 1;27(13):2163-2169. doi:10.1200/JCO.2008.17.4839.